MX357227B - Nanoparticulas basadas en lipidos. - Google Patents

Nanoparticulas basadas en lipidos.

Info

Publication number
MX357227B
MX357227B MX2013011231A MX2013011231A MX357227B MX 357227 B MX357227 B MX 357227B MX 2013011231 A MX2013011231 A MX 2013011231A MX 2013011231 A MX2013011231 A MX 2013011231A MX 357227 B MX357227 B MX 357227B
Authority
MX
Mexico
Prior art keywords
compositions
lipid
based nanoparticles
amyloid
liposomal
Prior art date
Application number
MX2013011231A
Other languages
English (en)
Spanish (es)
Other versions
MX2013011231A (es
Inventor
Annapragada Ananth
L Eriksen Jason
A Tanifum Eric
Dasgupta Indrani
c cook Stephen
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46966277&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX357227(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Texas filed Critical Univ Texas
Publication of MX2013011231A publication Critical patent/MX2013011231A/es
Publication of MX357227B publication Critical patent/MX357227B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0461—Dispersions, colloids, emulsions or suspensions
    • A61K49/0466—Liposomes, lipoprotein vesicles, e.g. HDL or LDL lipoproteins, phospholipidic or polymeric micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2013011231A 2011-04-06 2012-04-06 Nanoparticulas basadas en lipidos. MX357227B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161472605P 2011-04-06 2011-04-06
PCT/US2012/032649 WO2012139080A2 (en) 2011-04-06 2012-04-06 Lipid-based nanoparticles

Publications (2)

Publication Number Publication Date
MX2013011231A MX2013011231A (es) 2015-03-05
MX357227B true MX357227B (es) 2018-07-02

Family

ID=46966277

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013011231A MX357227B (es) 2011-04-06 2012-04-06 Nanoparticulas basadas en lipidos.

Country Status (14)

Country Link
US (1) US9801957B2 (OSRAM)
EP (2) EP3366313A1 (OSRAM)
JP (3) JP6212032B2 (OSRAM)
KR (2) KR102035187B1 (OSRAM)
CN (1) CN104144708B (OSRAM)
AU (3) AU2012239888B9 (OSRAM)
BR (1) BR112013025633A2 (OSRAM)
CA (1) CA2831480C (OSRAM)
DK (1) DK2694116T3 (OSRAM)
ES (1) ES2685824T3 (OSRAM)
MX (1) MX357227B (OSRAM)
PL (1) PL2694116T3 (OSRAM)
PT (1) PT2694116T (OSRAM)
WO (1) WO2012139080A2 (OSRAM)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2831480C (en) 2011-04-06 2020-09-29 Board Of Regents Of The University Of Texas System Lipid-based nanoparticles
ES2855165T3 (es) 2012-01-20 2021-09-23 Ananth Annapragada Métodos y composiciones para caracterizar objetivamente imágenes médicas
US9512092B2 (en) 2013-12-12 2016-12-06 Albert Einstein College Of Medicine, Inc. Retinoic acid receptor antagonists as chaperone-mediated autophagy modulators and uses thereof
CN107106708B (zh) * 2014-10-08 2021-06-18 德克萨斯州儿童医院 使用脂质体进行的淀粉样蛋白斑mri成像
GB201509934D0 (en) 2015-06-08 2015-07-22 King S College London Nanoparticles
EP3458074B1 (en) * 2016-05-16 2024-04-17 Board of Regents of the University of Texas System COMPOSITIONS FOR THE DELIVERY OF tRNA AS NANOPARTICLES AND METHODS OF USE THEREWITH
CN110022859B (zh) 2016-11-30 2022-10-28 德克萨斯州儿童医院 具有独特的mr特征用于脂质体19f mri探针的亲水性氟化分子
WO2020154623A1 (en) * 2019-01-24 2020-07-30 Alzeca Biosciences, LLC Functionalized liposomes for imaging misfolded proteins
US11116854B2 (en) * 2020-01-29 2021-09-14 Texas Children's Hospital Targeted contrast agents for MRI of amyloid deposition
US11779664B2 (en) 2020-02-12 2023-10-10 Texas Children's Hospital Targeted contrast agents for MRI of alpha-synuclein deposition
EP4103239A4 (en) * 2020-02-12 2024-03-20 Texas Children's Hospital TARGETED CONTRAST AGENTS FOR MAGNETIC RESONANCE IMAGING OF ALPHA-SYNUCLEIN DEPOSITS

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331751A (en) * 1980-11-17 1982-05-25 Eastman Kodak Company Electrically photosensitive materials and elements for photoelectrophoretic imaging processes
US5204085A (en) 1985-01-08 1993-04-20 Mallinckrodt Medical, Inc. Method for enhancing the safety of metal-ligand chelates as X-ray contrast agents
US5674468A (en) 1992-03-06 1997-10-07 Nycomed Imaging As Contrast agents comprising gas-containing or gas-generating polymer microparticles or microballoons
CN1148812A (zh) 1994-03-28 1997-04-30 尼科梅德成像有限公司 “脂质体”
US6071532A (en) 1996-10-15 2000-06-06 Emory University Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof
DE60017787T2 (de) 1999-11-30 2006-01-05 ARIZONA BOARD OF REGENTS, on behalf of THE UNIVERSITY OF ARIZONA, Tucson Strahlung-sensitive liposomen
US7029655B2 (en) 2000-10-04 2006-04-18 California Institute Of Technology Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits
AU2002314794A1 (en) * 2001-05-23 2002-12-03 New York University Detection of alzheimer's amyloid by magnetic resonance imaging
US7138136B2 (en) 2002-03-05 2006-11-21 Cleveland State University Agglomerated particles for aerosol drug delivery
WO2004096120A2 (en) 2003-05-01 2004-11-11 Nst Neurosurvival Technologies Ltd. Compounds that selectively bind to membranes of apoptotic cells
US7208174B2 (en) * 2003-12-18 2007-04-24 Hoffmann-La Roche Inc. Liposome compositions
US20100031378A1 (en) 2008-08-04 2010-02-04 Edwards Joel A Novel gene disruptions, compositions and methods relating thereto
US8357351B2 (en) 2004-04-21 2013-01-22 Ananth Annapragada Nano-scale contrast agents and methods of use
US7713517B2 (en) 2004-04-21 2010-05-11 Marval Biosciences, Inc. Compositions and methods for enhancing contrast in imaging
WO2006026184A2 (en) * 2004-08-20 2006-03-09 Washington University Blood brain barrier permeation peptides
US20070292354A1 (en) * 2004-09-23 2007-12-20 Guerbet Contrast Agents Encapsulating Systems for Cest Imaging
US9943481B2 (en) * 2005-05-26 2018-04-17 Biorest Ltd. Compositions and methods using same for delivering agents into a target organ protected by a blood barrier
WO2007048019A2 (en) * 2005-10-20 2007-04-26 The Penn State Research Foundation Delivery system for diagnostic and therapeutic agents
US20100062969A1 (en) * 2006-04-07 2010-03-11 Hayat Onyuksel Hydrophilic polymer-conjugated lipids for peptide and protein folding disorders
US20090123047A1 (en) 2007-03-21 2009-05-14 Yfantis Spyros A Method and system for characterizing prostate images
EP1982733A1 (en) 2007-04-17 2008-10-22 Bayer Schering Pharma Aktiengesellschaft Use of a contrast agent for magnetic resonance imaging of endoleaks
CA2695204A1 (en) 2007-07-26 2009-01-29 Nanoscan Imaging, Llc Methods for imaging using improved nanoparticulate contrast agents
CN101951835B (zh) 2007-12-05 2015-02-11 马维尔生物科学公司 纳米级对比剂和使用方法
CA2711503A1 (en) 2008-01-08 2009-07-16 Biogenerix Ag Glycoconjugation of polypeptides using oligosaccharyltransferases
ITMI20081052A1 (it) * 2008-06-10 2009-12-11 Univ Milano Bicocca Liposomi in grado di legare efficacemente il peptide beta-amiloide
US20090311191A1 (en) * 2008-06-13 2009-12-17 Ananth Annapragada Imaging of atherosclerotic plaques using liposomal imaging agents
US20110208064A1 (en) 2008-07-31 2011-08-25 Ran Chongzhao Curcumin Derivatives for Amyloid-Beta Plaque Imaging
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
EP2410990A4 (en) 2009-03-19 2015-05-20 Marval Biosciences Inc COMPOSITIONS AND METHODS FOR CONTRAST GAINING IN IMAGING
US9334304B2 (en) * 2009-04-02 2016-05-10 The Johns Hopkins University Self-assembling peptides bearing organic electronic functionality and applications employing the same
EP2501696B1 (en) 2009-10-15 2016-12-28 Guerbet Imaging agents and their use for the diagnostic in vivo of neurodegenerative diseases, notably alzheimer's disease and derivative diseases
EP2582674B1 (en) 2010-06-16 2014-10-01 Cymabay Therapeutics, Inc. Gpr120 receptor agonists and uses thereof
CA2822021C (en) 2011-03-02 2018-01-02 Sensulin, Llc Vesicle compositions
CA2831480C (en) 2011-04-06 2020-09-29 Board Of Regents Of The University Of Texas System Lipid-based nanoparticles
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
ES2855165T3 (es) 2012-01-20 2021-09-23 Ananth Annapragada Métodos y composiciones para caracterizar objetivamente imágenes médicas
WO2013164763A2 (en) 2012-04-30 2013-11-07 Innovative Health Diagnostics A biological complex specific for alzheimer's disease detection in vitro and use thereof
MX2015011677A (es) 2013-03-14 2016-07-08 Celtaxsys Inc Inhibidores de leucotrieno a4 hidrolasa.
CN107106708B (zh) 2014-10-08 2021-06-18 德克萨斯州儿童医院 使用脂质体进行的淀粉样蛋白斑mri成像

Also Published As

Publication number Publication date
CN104144708A (zh) 2014-11-12
CA2831480C (en) 2020-09-29
KR20140074868A (ko) 2014-06-18
JP6533813B2 (ja) 2019-06-19
AU2012239888B9 (en) 2017-10-12
JP6212032B2 (ja) 2017-10-18
KR20190031334A (ko) 2019-03-25
AU2012239888A1 (en) 2013-11-07
US9801957B2 (en) 2017-10-31
AU2012239888A2 (en) 2014-05-08
JP2018035167A (ja) 2018-03-08
ES2685824T3 (es) 2018-10-11
WO2012139080A2 (en) 2012-10-11
WO2012139080A3 (en) 2014-05-01
HK1203827A1 (en) 2015-11-06
AU2019246775A1 (en) 2019-10-31
JP2019151664A (ja) 2019-09-12
AU2017232156A1 (en) 2017-10-12
MX2013011231A (es) 2015-03-05
PT2694116T (pt) 2018-10-12
EP2694116B1 (en) 2018-06-13
DK2694116T3 (en) 2018-09-03
AU2012239888B2 (en) 2017-06-22
AU2017232156B2 (en) 2019-07-11
US20120258044A1 (en) 2012-10-11
CN104144708B (zh) 2017-07-28
EP3366313A1 (en) 2018-08-29
CA2831480A1 (en) 2012-10-11
KR101973063B1 (ko) 2019-04-30
PL2694116T3 (pl) 2018-12-31
JP2014523854A (ja) 2014-09-18
EP2694116A2 (en) 2014-02-12
EP2694116A4 (en) 2015-06-03
AU2017232156C1 (en) 2019-10-24
KR102035187B1 (ko) 2019-11-08
BR112013025633A2 (pt) 2017-08-08

Similar Documents

Publication Publication Date Title
MX357227B (es) Nanoparticulas basadas en lipidos.
WO2011130164A3 (en) Unconjugated anti-tfr antibodies and compositions thereof for the treatment of cancer
IL245889A0 (en) Sulfonamide derivatives as bcl-2-selective apoptosis inducers for the treatment of cancer and immune diseases
EP2707369A4 (en) COMPOSITIONS AND METHODS FOR TREATING ALZHEIMER'S DISEASE
MX340055B (es) Metodos y composiciones de nanoparticulas sin priones.
MX2014010455A (es) Metodos y composiciones para tratar enfermedad de huntington.
MY188911A (en) Methods of treating bladder cancer
MX2019000225A (es) Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.
WO2012006421A3 (en) Diagnosis and treatment of breast cancer
IL226377A0 (en) Preparations of isoflavone nanoparticles and methods for their preparation and use
MX371295B (es) Formación de imágenes por irm de placas amiloides usando liposomas.
SG11201403272YA (en) Compositions and methods for treating alzheimer's disease
IL220974A0 (en) Compositions and methods for the diagnosis and treatment of tumor
IL223819A0 (en) 3-amino-5,6-dihydro-1h-pyrazin-2-one derivatives useful for the treatement of alzheimer's disease and other forms of dementia
WO2010121164A3 (en) 1,4-benzodiazepinone compounds and their use in treating cancer
WO2011044537A9 (en) Methods for treating alzheimer's disease
PL2726470T3 (pl) Pochodne 1,2,4-tiadiazol-5-ilo piperazyny przydatne w leczeniu chorób neurodegeneracyjnych
EP4023243A3 (en) Compositions and methods for treating celiac sprue disease
WO2010105035A9 (en) Prevention, treatment, and diagnosis of alzheimer's disease through electromagnetic field exposure
WO2012040331A3 (en) Multistage nanoparticles
HK1215391A1 (zh) 使用胎盘细胞外基质治疗口腔病变
ZA201209452B (en) Gold complexes for use in the treatment of cancer
WO2012153253A3 (en) Aromatic compounds and metal complexes thereof
IL217149A0 (en) Compositions and methods for treating parkinson's disease
WO2011041701A3 (en) Inplantable contrast agents and methods

Legal Events

Date Code Title Description
FG Grant or registration